PROSELICA study update: Comparison of two doses of cabazitaxel (Cbz) plus prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a docetaxel (D)-containing regimen.
Mario A. Eisenberger
Research Funding - Sanofi
Anne-Claire Hardy-Bessard
Research Funding - Sanofi
Daniel Ford
Consultant or Advisory Role - GlaxoSmithKline; Janssen; Sanofi
Honoraria - GlaxoSmithKline; Janssen; Sanofi
Research Funding - Sanofi
Loic Mourey
No relevant relationships to disclose
Phillip Parente
Consultant or Advisory Role - Sanofi
Paul N. Mainwaring
Consultant or Advisory Role - Novartis; Roche; Sanofi
Honoraria - Novartis; Roche; Sanofi
Siobhan Ng
Consultant or Advisory Role - Sanofi (U)
Research Funding - Sanofi
Other Remuneration - Sanofi
Boris Alekseev
Research Funding - Sanofi
Vsevolod Matveev
No relevant relationships to disclose
Joan Carles
No relevant relationships to disclose
Jeremy Shapiro
No relevant relationships to disclose
Igor Latorzeff
Consultant or Advisory Role - AstraZeneca; Ferring; Ipsen; Sanofi ; Takeda
Honoraria - AstraZeneca; Ferring; Ipsen; Sanofi ; Takeda
Istvan Bodrogi
No relevant relationships to disclose
Choung-Soo Kim
No relevant relationships to disclose
Albert Font
No relevant relationships to disclose
Roanne Segal
No relevant relationships to disclose
Hendrik Pieter Van Den Berg
No relevant relationships to disclose
Wenping (Wendy) Zhang
Employment or Leadership Position - Sanofi
Mustapha Chadjaa
Employment or Leadership Position - Sanofi
Johann Sebastian De Bono
Employment or Leadership Position - The Institute of Cancer Research
Consultant or Advisory Role - Sanofi
Honoraria - Astellas Pharma; Johnson & Johnson; Sanofi
Research Funding - Sanofi